ASP Reimbursement Drags Down US Oncology’s Adjusted Income
This article was originally published in The Pink Sheet Daily
Executive Summary
US Oncology is raising its adjusted net income guidance for 2005, despite sustaining an unforeseen 2% drop in its average sales price during the second quarter, compared with the year-ago period